This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
BioMarin's First-Quarter Earnings & Sales Beat Estimates
by Zacks Equity Research
BMRN reports encouraging first-quarter results. The company reiterates its financial guidance for 2025.
BioMarin (BMRN) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for BioMarin (BMRN) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
BioMarin Pharmaceutical (BMRN) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
BioMarin (BMRN) delivered earnings and revenue surprises of 20.21% and 1.11%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Why BioMarin Pharmaceutical (BMRN) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Implied Volatility Surging for BioMarin Stock Options
by Zacks Equity Research
Investors need to pay close attention to BMRN stock based on the movements in the options market lately.
Danaher Gears Up to Post Q1 Earnings: Is a Beat in Store?
by Zacks Equity Research
DHR's first-quarter earnings are likely to have been aided by strength in the Biotechnology segment. However, weakness in the Diagnostics and Life Sciences segments are expected to have hurt.
Why BioMarin Pharmaceutical (BMRN) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Bristol Myers Squibb (BMY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Bristol Myers (BMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BioMarin Pharmaceutical (BMRN) Earnings Expected to Grow: What to Know Ahead of Q1 Release
by Zacks Equity Research
BioMarin (BMRN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Legend Biotech (LEGN) Moves 5.1% Higher: Will This Strength Last?
by Zacks Equity Research
Legend Biotech (LEGN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Will BioMarin (BMRN) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
BioMarin (BMRN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Strength Seen in BioMarin (BMRN): Can Its 6.3% Jump Turn into More Strength?
by Zacks Equity Research
BioMarin (BMRN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Astronics and Boston Beer have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Astronics and Boston Beer have been highlighted as Zacks Bull and Bear of the Day.
Will Trump Tariffs Make or Break Healthcare Space? 3 Stocks to Rely On
by Urmimala Biswas
Investors looking to maintain exposure to healthcare can invest in large-cap U.S.-based companies like UHS, BMRN and ABT.
Viatris to Pay $335 Million for Settlement of Opioid-Related Claims
by Zacks Equity Research
VTRS has reached an agreement of $335 million to resolve opioid-related claims by states, local governments, and tribes against it and certain of its subsidiaries.
5 Biotech Stocks Worth Adding Amid Global Uncertainty in 2025
by Ekta Bagri
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position GILD, BMRN, KRYS, ADMA and FOLD well in this volatile sector.
3 Reasons Why Growth Investors Shouldn't Overlook BioMarin (BMRN)
by Zacks Equity Research
BioMarin (BMRN) possesses solid growth attributes, which could help it handily outperform the market.
What Makes BioMarin (BMRN) a New Buy Stock
by Zacks Equity Research
BioMarin (BMRN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
BMRN vs. CSLLY: Which Stock Is the Better Value Option?
by Zacks Equity Research
BMRN vs. CSLLY: Which Stock Is the Better Value Option?
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
BMRN's PKU Drug Palynziq Meets Goal in Late-Stage Pediatric Study
by Zacks Equity Research
Based on the late-stage data, BioMarin plans to submit a regulatory filing for expanding the label of its PKU drug Palynziq in adolescents before this year's end.
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Momentum Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Femasys Inc. (FEMY) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Femasys (FEMY) delivered earnings and revenue surprises of 8% and 41.80%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
BioMarin (BMRN) Up 4.2% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.